Core Insights - The National Healthcare Security Administration has officially announced the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, adding 114 new drugs, bringing the total to 3,253, covering various treatment areas including cancer, chronic diseases, and rare diseases [1][2] Group 1: Drug Inclusion and Coverage - The updated catalog includes multiple new blood cancer drugs, such as Maleate Acalabrutinib Tablets, which are significant for patients with chronic lymphocytic leukemia and other blood cancers [1] - The inclusion of Maleate Acalabrutinib Tablets for CLL/SLLL marks a comprehensive coverage for various stages of blood cancer treatment, addressing previously unmet needs [2] Group 2: Impact on Patients and Healthcare - The update enhances clinical treatment options for blood cancer patients, filling gaps in the treatment of chronic lymphocytic leukemia and supporting the goal of improving cancer survival rates as part of the "Healthy China 2030" initiative [2] - The new drug additions are expected to alleviate the economic burden on patients and provide more accessible medication support for clinical treatment [2]
医保目录调整 为血液肿瘤患者提供可及用药支持
Ke Ji Ri Bao·2025-12-08 03:32